 Connection
William Robinson to Antineoplastic Agents
This is a "connection" page, showing publications William Robinson has written about Antineoplastic Agents.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
1.134 |
|
|
|
-
Lee H, King G, Garg K, Pan Z, Tobin J, Robinson WA. Successful treatment of disseminated Rosai-Dorfman disease with siltuximab. Haematologica. 2018 07; 103(7):e325-e328.
Score: 0.258
-
Swick BL, Ravdel L, Fitzpatrick JE, Robinson WA. Platelet-derived growth factor receptor alpha mutational status and immunohistochemical expression in Merkel cell carcinoma: implications for treatment with imatinib mesylate. J Cutan Pathol. 2008 Feb; 35(2):197-202.
Score: 0.127
-
Swick BL, Ravdel L, Fitzpatrick JE, Robinson WA. Merkel cell carcinoma: evaluation of KIT (CD117) expression and failure to demonstrate activating mutations in the C-KIT proto-oncogene - implications for treatment with imatinib mesylate. J Cutan Pathol. 2007 Apr; 34(4):324-9.
Score: 0.120
-
Mukherjee N, Katsnelson E, Brunetti TM, Michel K, Couts KL, Lambert KA, Robinson WA, McCarter MD, Norris DA, Tobin RP, Shellman YG. MCL1 inhibition targets Myeloid Derived Suppressors Cells, promotes antitumor immunity and enhances the efficacy of immune checkpoint blockade. Cell Death Dis. 2024 03 08; 15(3):198.
Score: 0.097
-
Mukherjee N, Dart CR, Amato CM, Honig-Frand A, Lambert JR, Lambert KA, Robinson WA, Tobin RP, McCarter MD, Couts KL, Fujita M, Norris DA, Shellman YG. Expression Differences in BCL2 Family Members between Uveal and Cutaneous Melanomas Account for Varying Sensitivity to BH3 Mimetics. J Invest Dermatol. 2022 07; 142(7):1912-1922.e7.
Score: 0.083
-
Mukherjee N, Skees J, Todd KJ, West DA, Lambert KA, Robinson WA, Amato CM, Couts KL, Van Gulick R, MacBeth M, Nassar K, Tan AC, Zhai Z, Fujita M, Bagby SM, Dart CR, Lambert JR, Norris DA, Shellman YG. MCL1 inhibitors S63845/MIK665 plus Navitoclax synergistically kill difficult-to-treat melanoma cells. Cell Death Dis. 2020 06 08; 11(6):443.
Score: 0.075
-
Mackin AG, Pecen PE, Dinsmore AL, Patnaik JL, Gonzalez R, Robinson WA, Palestine AG. Inflammatory side effects of BRAF and MEK inhibitors. Melanoma Res. 2019 10; 29(5):522-526.
Score: 0.072
-
Gibbs P, Chen Q, Robinson WA. Effects of oncostatin M and tamoxifen on human melanoma cells. Melanoma Res. 1998 Jun; 8(3):221-6.
Score: 0.065
-
Mukherjee N, Lu Y, Almeida A, Lambert K, Shiau CW, Su JC, Luo Y, Fujita M, Robinson WA, Robinson SE, Norris DA, Shellman YG. Use of a MCL-1 inhibitor alone to de-bulk melanoma and in combination to kill melanoma initiating cells. Oncotarget. 2017 Jul 18; 8(29):46801-46817.
Score: 0.061
-
Mukherjee N, Reuland SN, Lu Y, Luo Y, Lambert K, Fujita M, Robinson WA, Robinson SE, Norris DA, Shellman YG. Combining a BCL2 inhibitor with the retinoid derivative fenretinide targets melanoma cells including melanoma initiating cells. J Invest Dermatol. 2015 Mar; 135(3):842-850.
Score: 0.051
-
Weiss GJ, Bemis LT, Nakajima E, Sugita M, Birks DK, Robinson WA, Varella-Garcia M, Bunn PA, Haney J, Helfrich BA, Kato H, Hirsch FR, Franklin WA. EGFR regulation by microRNA in lung cancer: correlation with clinical response and survival to gefitinib and EGFR expression in cell lines. Ann Oncol. 2008 Jun; 19(6):1053-9.
Score: 0.032
-
Lewis KD, Thompson JA, Weber JS, Robinson WA, O'Day S, Lutzky J, Legha SS, Floret S, Ruvuna F, Gonzalez R. A phase II open-label trial of apomine (SR-45023A) in patients with refractory melanoma. Invest New Drugs. 2006 Jan; 24(1):89-94.
Score: 0.028
-
Robinson WA, Miller TL, Harrold EA, Bemis LT, Brady BM, Nelson RP. The effect of flavopiridol on the growth of p16+ and p16- melanoma cell lines. Melanoma Res. 2003 Jun; 13(3):231-8.
Score: 0.023
-
Luo Y, Ellis LZ, Dallaglio K, Takeda M, Robinson WA, Robinson SE, Liu W, Lewis KD, McCarter MD, Gonzalez R, Norris DA, Roop DR, Spritz RA, Ahn NG, Fujita M. Side population cells from human melanoma tumors reveal diverse mechanisms for chemoresistance. J Invest Dermatol. 2012 Oct; 132(10):2440-2450.
Score: 0.011
-
Feun LG, Gonzalez R, Savaraj N, Hanlon J, Collier M, Robinson WA, Clendeninn NJ. Phase II trial of piritrexim in metastatic melanoma using intermittent, low-dose administration. J Clin Oncol. 1991 Mar; 9(3):464-7.
Score: 0.010
-
Robinson WA, Mughal TI, Thomas MR, Johnson M, Spiegel RJ. Treatment of metastatic malignant melanoma with recombinant interferon alpha 2. Immunobiology. 1986 Sep; 172(3-5):275-82.
Score: 0.007
-
Thomas MR, Robinson WA, Glode LM, Dantas ME, Koeppler H, Morton N, Sutherland J. Treatment of advanced malignant melanoma with high-dose chemotherapy and autologous bone marrow transplantation. Preliminary results--Phase I study. Am J Clin Oncol. 1982 Dec; 5(6):611-22.
Score: 0.006
-
Glode LM, Robinson WA, Hartmann DW, Klein JJ, Thomas MR, Morton N. Autologous bone marrow transplantation in the therapy of small cell carcinoma of the lung. Cancer Res. 1982 Oct; 42(10):4270-5.
Score: 0.006
-
Kurnick JE, Robinson WA. Cell kill hypothesis. Arch Intern Med. 1972 Nov; 130(5):790.
Score: 0.003
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|